Sotera Health Co
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Piper Sandler reiterated an Overweight rating and $25.00 price target on Sotera Health (SHC), suggesting 19% upside. The firm cited strong growth, management's strategy, and positive free cash flow outlook. SHC reported Q2 earnings beating estimates, with revenue up 9.2% YoY. Management raised its 2026 outlook and announced reaching long-term leverage targets.
Bio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.
Petras Michael B. Jr. (Executive Chairman) sold 850,000 indirectly-held shares of Sotera Health Co (SHC) at $18.50 ($15.73M total) on 2026-08-17.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SHC (Sotera Health Co). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SHC coverage spans earnings, insider activity and corporate actions.
In the last 30 days, SHC insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($21.2M). The most active reporter was Petras Michael B. Jr., Executive Chairman, with 2 filings.
Analyst upgrade and strong Q2 results suggest upside potential.
Positive earnings surprise lifted the share price.
Large insider sell may pressure the stock short-term.
Significant insider sell may signal lack of confidence or need for liquidity, potentially pressuring the stock lower.
Modest earnings beat could sustain mild upside.
AlphAI scores every news story that mentions SHC with an AI model for sentiment and relevance, and aggregates insider trades from Sotera Health Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Piper Sandler reiterated an Overweight rating and $25.00 price target on Sotera Health (SHC), suggesting 19% upside. The firm cited strong growth, management's strategy, and positive free cash flow outlook. SHC reported Q2 earnings beating estimates, with revenue up 9.2% YoY. Management raised its 2026 outlook and announced reaching long-term leverage targets.
2 min readBio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.
3 min readPetras Michael B. Jr. (Executive Chairman) sold 850,000 indirectly-held shares of Sotera Health Co (SHC) at $18.50 ($15.73M total) on 2026-08-17.
1 min readPetras Michael B. Jr. (Executive Chairman) sold 294,515 shares of Sotera Health Co (SHC) at $18.50 ($5.45M total) on 2026-08-17.
1 min readAvantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.
3 min readSotera Health (SHC) reported Q2 2026 revenue of $321.38 million, up from $294.34 million, and net income of $53.64 million versus $7.96 million a year earlier. The company cited strength across Sterigenics, Nordion, and Nelson Labs and raised its full-year outlook. The article also notes a May 2026 repricing of first lien term loans and discusses regulatory and litigation risks tied to ethylene oxide.
4 min readSotera Health Co (SHC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 11, 2026, James C. Neary notified the Board of Directors (the “Board”) of Sotera Health Company (the “Company”)
2 min readChina is accelerating brain-computer interface (BCI) development via state-backed initiatives. PICC Property and Casualty, a state-owned insurer, said it signed China’s first commercial insurance policy covering invasive BCI implant surgery, with a hospital affiliated with Zhejiang University in Hangzhou. BCI-linked Hong Kong stocks rose 1.59% on Wednesday, including Shanghai Heartcare (+1.28%) and BrainAurora (+1.65%).
3 min readRutz Michael P (President of Sterigenics) sold 150,000 shares of Sotera Health Co (SHC) at $18.84 ($2.83M total) on 2026-08-07.
2 min readMcIntyre Partnerships’ Q2 2026 investor letter highlighted Sotera Health (NASDAQ:SHC). It cited Sterigenics returning to HSD organic growth, Georgia litigation where a judge dismissed 5 lawsuits, and a CEO transition. The article notes SHC closed at $18.86 on Aug. 7, 2026, and discusses an estimated sub-$50M current liability and ~$180M worst-case settlement versus ~$640M 2026 EBITDA.
4 min read
